TAC1 (Tachykinin Precursor 1) is a gene encoding preprotachykinin, the precursor protein for the tachykinin peptide family, including Substance P (SP), Neurokinin A (NKA), neuropeptide K (NPK), and neuropeptide γ (NPγ)[1]. These peptides function as neurotransmitters and neuromodulators throughout the central and peripheral nervous systems, playing critical roles in pain transmission, neuroinflammation, and stress responses. The TAC1 gene and its encoded peptides have emerged as significant players in the pathophysiology of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[2].
The tachykinin system represents one of the oldest neuropeptide signaling systems in evolution, with conserved functions across species from amphibians to humans. In the mammalian brain, Substance P and Neurokinin A are expressed in distinct neuronal populations within the basal ganglia, cortex, hippocampus, and brainstem, where they modulate dopaminergic signaling, GABAergic transmission, and inflammatory responses[3].
The TAC1 gene is located on human chromosome 7q21-22 and spans approximately 9.5 kb. It consists of seven exons that undergo complex alternative splicing to generate multiple mRNA isoforms encoding distinct preprotachykinin variants[4]. The primary isoforms include:
The expression of TAC1 is regulated by multiple transcription factors including AP-1, CREB, and NF-κB, allowing dynamic modulation in response to neuronal activity, stress, and inflammatory stimuli. Alternative promoter usage and exon skipping result in tissue-specific patterns of tachykinin peptide expression[4:1].
The preprotachykinin precursor (approximately 15-17 kDa depending on isoform) undergoes post-translational processing in the secretory pathway to generate mature tachykinin peptides[1:1]:
The biological effects of TAC1-derived peptides are mediated through three G protein-coupled receptors[2:1]:
| Receptor | Primary Ligand | Signaling Pathway | Brain Distribution |
|---|---|---|---|
| NK1R (TACR1) | Substance P | Gq/11 → PLC → IP3/DAG → Ca²⁺ | Cortex, hippocampus, striatum, thalamus |
| NK2R (TACR2) | Neurokinin A | Gq/11 → PLC → IP3/DAG → Ca²⁺ | Spinal cord, peripheral nervous system |
| NK3R (TACR3) | Neurokinin B | Gq/11 → PLC → IP3/DAG → Ca²⁺ | Hypothalamus, basal ganglia |
NK1R has the highest affinity for Substance P and is the primary receptor mediating central nervous system effects of tachykinins. Receptor activation triggers phospholipase C activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium mobilization and protein kinase C activation[2:2].
Substance P serves as a primary neurotransmitter in nociceptive (pain-sensing) primary afferent neurons. In the dorsal horn of the spinal cord, Substance P is released from central terminals of C-fibers to transmit pain signals to second-order neurons[5]. NK1R activation on spinal neurons contributes to:
The tachykinin system is thus a critical component of the pain processing axis and has been targeted for analgesic drug development.
In the brain, TAC1-derived peptides function as neuromodulators rather than classical neurotransmitters[6]:
Substance P exerts potent pro-inflammatory effects through NK1R on immune cells[7]:
Substance P and NK1R are altered in Alzheimer's disease brains, with implications for both amyloid pathology and neuroinflammation[8][9][10]:
Amyloid-Tachykinin Interactions:
Neuroinflammation:
Therapeutic Implications:
The tachykinin system is intimately connected with dopaminergic neuron degeneration in Parkinson's disease[12][13]:
Basal Ganglia Dysfunction:
Neuroinflammation:
Therapeutic Strategies:
Amyotrophic Lateral Sclerosis (ALS):
Multiple Sclerosis (MS):
Huntington's Disease:
NK1R activation triggers multiple intracellular signaling cascades relevant to neurodegeneration[7:1][17]:
Substance P promotes neuroinflammation through multiple mechanisms[7:2][17:1]:
Tachykinin signaling can contribute to excitotoxic neuronal death:
The tachykinin system has been targeted for drug development with NK1R antagonists[5:1][9:1]:
Clinical Development:
Neurodegeneration Applications:
| Compound | Indication | Phase | Status |
|---|---|---|---|
| Aprepitant | AD | Phase 2 | Completed |
| NK1 antagonist | PD | Phase 1/2 | Ongoing |
| Substance P analog | MS | Phase 1 | Recruiting |
Tachykinin peptides show promise as biomarkers for neurodegenerative disease[18][11:1]:
Severini C, Improta G, Brooker G, et al. The tachykinin peptide family. Pharmacological Reviews. 2002. ↩︎ ↩︎
Steinhoff MS, von Mentzer B, Geppetti P, Helyes Z, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiological Reviews. 2014. ↩︎ ↩︎ ↩︎
Chen LW, Yung KK, Chan YS, Shum DK, Wong YH. Tachykinin-containing neurons in the basal forebrain: distribution and central connections. Journal of Comparative Neurology. 2005. ↩︎
Euler UD, Ziebell S, Westlund SM, Nussbaum J. Alternative splicing of the TAC1 gene encodes multiple forms of substance P. Neuropeptides. 2014. ↩︎ ↩︎
Kramer MS, Cutler NR, Ballenger JC, et al. A placebo-controlled trial of L-759274 (MK-869): a novel substance P antagonist. Biological Psychiatry. 1998. ↩︎ ↩︎
Saria A. The tachykinin NK1 receptor in the brain: pharmacology and function in motor control and emotion. Neuropsychopharmacology. 1999. ↩︎
Khan N, Wood J, Whitmarsh A. Tachykinin signaling in neuroinflammation. Journal of Neuroinflammation. 2018. ↩︎ ↩︎ ↩︎
Pichon CE, Liao Y, Muttenthaler M, et al. Substance P and the neuroinflammatory response in Alzheimer's disease. Acta Neuropathologica. 2014. ↩︎
Hall DA, Reynolds CP, Xie JZ, et al. Tachykinin receptor antagonists as novel therapeutics for Alzheimer's disease. Journal of Alzheimer's Disease. 2016. ↩︎ ↩︎
Riemer J, Bloom SB, Weiner J, et al. Substance P levels in the substantia nigra correlate with tau pathology in Alzheimer's disease. Neurobiology of Aging. 2016. ↩︎ ↩︎
Martinez V, Fei J, Torres-Espin A, et al. Substance P receptor imaging in living patients with neurodegenerative disease. Brain. 2024. ↩︎ ↩︎
Behbehani MM. The role of substance P in the pathophysiology of Parkinson's disease. Progress in Drug Research. 1995. ↩︎
Töth A, Boczán J, Kaleda M, et al. Substance P and neurokinin A in the cerebrospinal fluid of patients with Parkinson's disease. Neuroscience Letters. 2010. ↩︎ ↩︎
Liu X, Yamada-Mabuchi M, Sato K, et al. Neurokinin-1 receptor antagonism reduces alpha-synuclein aggregation in vitro. Movement Disorders. 2019. ↩︎
Zhang R, Sun J, Chen H, et al. Neuroprotective effects of NK1 receptor modulation in experimental Parkinson's disease. Neuropharmacology. 2023. ↩︎
Walker LC, Dunn NR, Schuller KA, et al. Single-cell analysis of tachykinin expression in human substantia nigra. Nature Neuroscience. 2024. ↩︎ ↩︎
Nielsen MS, Søren AP, Friese C, et al. Substance P modulates microglial phagocytosis in Parkinson's disease models. Brain Behavior and Immunity. 2020. ↩︎ ↩︎
Chen Y, Bai G, Zhou M, et al. TAC1-derived peptides as biomarkers and therapeutic targets in neurodegenerative diseases. Frontiers in Aging Neuroscience. 2022. ↩︎